Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
暂无分享,去创建一个
S. Sahn | R. D. du Bois | A. Wells | W. Bradford | L. Lancaster | M. Thomeer | D. Valeyre | T. King | U. Costabel | P. Noble | C. Albera | D. Weycker | A. Kartashov
[1] Russian Federation.,et al. European Respiratory Society Annual Congress 2013 , 2013 .
[2] S. Sahn,et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.
[3] S. Sahn,et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.
[4] H. Collard,et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[5] G. Raghu,et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.
[6] D. Fairclough,et al. Pirfenidone in idiopathic pulmonary fibrosis , 2010, European Respiratory Journal.
[7] A. Nicholson,et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.
[8] A. Holland,et al. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. , 2009, Respiratory medicine.
[9] S. Sahn,et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.
[10] G. Raghu,et al. Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan , 2009 .
[11] J. Epstein,et al. Separating gains and losses in health when calculating the minimum important difference for mapped utility measures , 2008, Quality of Life Research.
[12] Malcolm Man-Son-Hing,et al. Determination of the clinical importance of study results , 2002, Journal of General Internal Medicine.
[13] Johny Verschakelen,et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.
[14] D. Eton,et al. Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.
[15] S. Kudoh,et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.
[16] W. Travis,et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.
[17] G. Guyatt,et al. Commentary--goodbye M(C)ID! Hello MID, where do you come from? , 2005, Health services research.
[18] A. Ries,et al. Minimally Clinically Important Difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale , 2005, COPD.
[19] G. Raghu,et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. , 2005, Chest.
[20] G. Raghu,et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.
[21] A. Nicholson,et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.
[22] F. Martinez,et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.
[23] H. Collard,et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.
[24] J. Brazier,et al. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D , 2003, Health and quality of life outcomes.
[25] Gordon H Guyatt,et al. Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.
[26] J. Tooze,et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. , 2001, American journal of respiratory and critical care medicine.
[27] Arnold Simanowitz,et al. international consensus statement , 2000 .
[28] David A. Lynch,et al. Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .
[29] G. Raghu,et al. Assessment of health-related quality of life in patients with interstitial lung disease. , 1999, Chest.
[30] W. Tierney,et al. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. , 1999, Journal of clinical epidemiology.
[31] W M Tierney,et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. , 1999, Medical care.
[32] R. Kaplan,et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. , 1998, Chest.
[33] R. Kaplan,et al. The UCSD Shortness of Breath Questionnaire , 1998 .
[34] P. Allison. Survival analysis using the SAS system : a practical guide , 1995 .
[35] P. Lachenbruch. Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .